Abstract: In a threaded joint for pipes constituted by a pin and a box, each having a contact surface comprising a threaded portion and an unthreaded metal contact portion, the contact surface of the pin has a solid corrosion protective, preferably transparent coating based on a UV-curable resin and the contact surface of the box has a solid lubricating coating having plastic or viscoplastic rheological behavior which is preferably formed by the hot melt technique from a composition comprising a thermoplastic polymer, a wax, a metal soap, a corrosion inhibitor, a water-insoluble liquid resin, and a solid lubricant.

Abstract: A hydroponic system (1) is provided with a light-collecting apparatus (3) having a pair of reflecting plates (31a) that are vertically arranged in parallel with a culture surface (23) of a culture panel (21) of a hydroponic unit (2). During a process in which natural light taken from a light-collecting opening (30) propagates while repeatedly reflected by opposing reflecting surfaces of a reflecting plates (31a), by allowing seedlings p that are transplanted into the culture panel (21) to be irradiated with the light through a light-emitting hole (32) bored in the reflecting plate (31a), a culture object can be grown efficiently at a low cost by taking natural light from the outside.

Abstract: The invention provides a composition capable of providing a molded article that has excellent heat resistance and a small weight change against both fluorine plasma exposure and oxygen plasma exposure during a semiconductor manufacturing step. The composition contains a fluorine-containing polymer and a cage silsesquioxane having a specific structure.

Abstract: Provided is a ferritic stainless steel that has good corrosion resistance and which exhibits good brazeability when subjected to high-temperature brazing with a Ni-containing brazing filler metal. The ferritic stainless steel has a composition containing, in mass %, C: 0.003 to 0.020%, Si: 0.05 to 0.60%, Mn: 0.05 to 0.50%, P: 0.04% or less, S: 0.02% or less, Cr: 17.0 to 24.0%, Ni: 0.20 to 0.80%, Cu: 0.01 to 0.80%, Mo: 0.01 to 2.50%, Al: 0.001 to 0.015%, Nb: 0.25 to 0.60%, and N: 0.020% or less, with the balance being Fe and incidental impurities, the composition satisfying formula (1) below and formula (2) below, Cu+Mo?0.30??(1) 4Ni?(Si+Mn)?0??(2) (wherein Cu and Mo in formula (1) and Ni, Si, and Mn in formula (2) each represent the content (mass %) of the corresponding element).

Abstract: A screen transition diagram creator that creates a screen transition diagram illustrating complicated transition relations in an easy-to-understand manner, including: a screen transition diagram editor providing the screen transition diagram in which transition relations among plural screens are illustrated by plural screen nodes and arrows between the screen nodes; a screen transition pattern applying unit applying a predetermined screen transition pattern to a target screen node group that includes at least part of the screen nodes illustrated in the screen transition diagram to provide a pattern-applied screen node group; and a screen transition structure diagram creator creating a screen transition structure diagram by abridgement processing on the pattern-applied screen node group according to a display layout corresponding to the screen transition pattern.

Abstract: A monitoring control system includes a control device that performs a device control process, and a high-order system that monitors the device control process. The control device includes a control CPU that performs the device control process, and an information CPU that is connected to the control CPU via an internal bus. The control CPU includes a device memory that stores therein device data to be used for the device control process, the device data being related to the device. The information CPU includes a built-in database and a data collection unit. The data collection unit performs a data collection process of reading the device data from the device memory via the internal bus, and storing the read device data in the built-in database.

Abstract: A monitoring control system includes a control device that performs a device control process, and a high-order system that monitors the device control process. The control device includes a control CPU that performs the device control process, and an information CPU that is connected to the control CPU via an internal bus. The control CPU includes a device memory that stores therein device data to be used for the device control process, the device data being related to the device. The information CPU includes a built-in database and a data collection unit. The data collection unit performs a data collection process of reading the device data from the device memory via the internal bus, and storing the read device data in the built-in database.

Abstract: A screen transition diagram creator that creates a screen transition diagram illustrating complicated transition relations in an easy-to-understand manner, including: a screen transition diagram editor providing the screen transition diagram in which transition relations among plural screens are illustrated by plural screen nodes and arrows between the screen nodes; a screen transition pattern applying unit applying a predetermined screen transition pattern to a target screen node group that includes at least part of the screen nodes illustrated in the screen transition diagram to provide a pattern-applied screen node group; and a screen transition structure diagram creator creating a screen transition structure diagram by abridgement processing on the pattern-applied screen node group according to a display layout corresponding to the screen transition pattern.

Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.

Abstract: Methods of promoting liver morphogenesis prior to the functioning of blood vessels by culturing liver cells with endothelial cells is provided. Also provided are cell cultures and method of promoting vasculogenesis of liver tissue by contacting liver cells with endothelial cells.

Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.

Abstract: The invention provides a modified glycosylation-deficient HGF and a production method thereof. The glycosylation-deficient HGF is produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.

Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.

Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.